GlassScriptPhysician profile
Dariush Bahrami
NPI 1659354850
$1,719.85
in general payments reported to CMS, 2019-2025
19 companies · $426 in 2025
The $426 reported for 2025 was more than what a typical Nephrology (Internal Medicine) provider received nationally (typical 2025 total: $311).
See the full distribution for Nephrology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $225 · 2020: $114 · 2021: $118 · 2022: $93.72 · 2023: $205 · 2024: $538 · 2025: $426.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,095 · Education: $73.21.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,094.92 |
| Education | $73.21 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $314.19 | 2023-2025 | |
| Astrazeneca Pharmaceuticals LP | $243.37 | 2020-2025 | Farxiga, Lokelma |
| Otsuka America Pharmaceutical, INC. | $178.27 | 2019-2025 | Jynarque, Voyxact |
| Amgen INC. | $143.04 | 2019-2025 | Krystexxa |
| Opko Pharmaceuticals, LLC | $110.90 | 2019-2021 | |
| Travere Therapeutics, INC. | $102.67 | 2019-2025 | Filspari |
| Horizon Therapeutics Plc | $96.12 | 2019-2021 | |
| Baxter Healthcare | $80.59 | 2024 | Renal - Chronic |
| Aurinia Pharma U.S., INC. | $64.40 | 2022-2025 | Lupkynis |
| Bayer Healthcare Pharmaceuticals INC. | $61.46 | 2021-2025 | |
| Novo Nordisk INC | $57.90 | 2022-2024 | Ozempic, Rybelsus |
| Calliditas Therapeutics US INC. | $54.46 | 2024-2025 | Tarpeyo |
| Ardelyx, INC. | $47.74 | 2024-2025 | Ibsrela |
| Vantive US Healthcare LLC | $47.00 | 2025 | Renal - Pd |
| Boehringer Ingelheim Pharmaceuticals, INC. | $35.03 | 2024 | Jardiance |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vifor Pharma, INC. | $26.35 | 2020 | |
| Scpharmaceuticals INC. | $20.11 | 2025 | |
| Akebia Therapeutics INC | $19.00 | 2019 | |
| Fresenius USA Marketing, INC. | $17.25 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Dariush Bahrami listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.